Trials / Unknown
UnknownNCT01297855
Colistin Plus Rifampicin in MDR P. Aeruginosa and A. Baumanii
Randomized Controlled Trial of Colistin Versus Colistin Plus Rifampicin in MDR P.Aeruginosa and A.Baumanii
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- Sponsor
- Mahidol University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
In Siriraj Hospital, Colistin alone for treatment of MDR. A.baumanii or P.aeruginosa contributed to mortality 45%. In vitro studies revealed synergism of Rifampicin and Colistin. In this study, patients with documented MDR. P.aeruginosa or A.baumanii will be allocated to receive Colistin alone and another group will receive Colistin plus Rifampicin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Colistin | Colistimethate Sodium dose 2.5-5mg/kg/day |
| DRUG | Colistin plus Rifampicin | Colistin 2.5 to 5 mg/ Kg/ day Rifampin 10 mg/ Kg/ day |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2012-05-01
- Completion
- 2012-08-01
- First posted
- 2011-02-17
- Last updated
- 2012-01-02
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT01297855. Inclusion in this directory is not an endorsement.